Immuno-Oncology
CAR-T and lymphoma treatment in the UK
Lymphoma treatment has seen many recent advances, with CAR-T therapy being a game changer for patients. Several clinical trials investigating…
Date: 27th May 2022
Harnessing the power of immunotherapy in myeloma and amyloidosis
The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging,…
Date: 20th May 2022
Genomics in the age of immuno-oncology
Immunotherapies are at the forefront of myeloma treatment and there are many questions remaining. Defining high-risk is important when making…
Date: 29th April 2022
Recent advances in amyloidosis treatment
Amyloidosis is a disease that results from the accumulation of a toxic, insoluble protein called amyloid in various tissues and…
Date: 1st April 2022
ASH 2021: a deep dive into ALL immunotherapy
Various forms of immunotherapy represent a novel treatment option, especially for patients who progress from conventional chemotherapy hematopoietic stem-cell transplantation…
Date: 25th March 2022
ASH 2021: what did ASH 2021 mean for MDS?
With high rates of relapse in patients with myelodysplastic syndromes (MDS), there is a great unmet need for novel treatments…
Date: 18th March 2022
ASH 2021: the future of cell therapies in lymphoma
Cell therapies including chimeric antigen receptor (CAR) T-cell therapy represent novel treatments for patients with lymphoma, especially for those who…
Date: 25th February 2022
The Lymphoma Sessions: post-ASH 2021
The 63rd American Society of Hematology (ASH) annual meeting saw a plethora of updates in lymphoma. While most of them…
Date: 2nd February 2022
COSTEM: the role of alloHSCT in ALL
Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of…
Date: 25th October 2021
SOHO 2021: amyloidosis treatment updates
Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of…
Date: 30th September 2021
IACH 2021: CAR-T in clinical practice
Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…
Date: 30th September 2021
Unmet needs and recent updates in CML
The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib…
Date: 29th September 2021